5-year survival outcomes after perioperative pembrolizumab (pembro) in patients with human papillomavirus (HPV)-unrelated, locally advanced head and neck squamous cell carcinoma (LA-HNSCC): A multi-center, two-cohort, phase 2 trial.
Edward S. Sim(Massachusetts Eye and Ear Infirmary), Douglas R. Adkins(Washington University in St. Louis), Vickie Y. Jo(Brigham and Women's Hospital), Rebecca D. Chernock(Washington University in St. Louis), Sidharth V. Puram(Washington University in St. Louis), Ann Marie Egloff(Brigham and Women's Hospital), Jonathan D. Schoenfeld(Brigham and Women's Hospital), Laura A. Goguen(Brigham and Women's Hospital), Glenn J. Hanna(Dana-Farber Cancer Institute), Patrik Pipkorn(Washington University in St. Louis), Donald J. Annino(Harvard University), José P. Zevallos(University of Pittsburgh Medical Center), Lara Dunn(Memorial Sloan Kettering Cancer Center), Ravindra Uppaluri(Brigham and Women's Hospital), Robert I. Haddad(Georgetown University), Luc G.T. Morris(Memorial Sloan Kettering Cancer Center), Jessica Ley(Washington University in St. Louis), Tanujit Dey(Brigham and Women's Hospital), Ryan S. Jackson(Washington University in St. Louis)
Cited by 0
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer
|Cell|2017|2.6k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k